Prognostic Markers in Follicular Lymphoma

Introduction to Prognostic Markers

Beta-2 microglobulin (B2M) is the superior prognostic marker among LDH, B2M, and CD19, as it is incorporated into modern validated prognostic scoring systems (FLIPI 2 and PRIMA-PI), according to the European Society for Medical Oncology (ESMO) guidelines 1, 2

B2M is a core component of FLIPI 2, one of five risk factors that stratifies patients into low, intermediate, and high-risk categories, as recommended by the American Society of Clinical Oncology (ASCO) 1, 2
B2M serves as the primary stratification tool in PRIMA-PI, where elevated B2M alone defines high-risk disease, as stated by the National Comprehensive Cancer Network (NCCN) 1, 3, 2
Elevated B2M independently predicts survival outcomes and is used to guide treatment intensity decisions in follicular lymphoma, according to the ESMO guidelines 2
ESMO guidelines require B2M measurement at diagnosis alongside complete blood count, LDH, uric acid, and immunoglobulin levels as part of standard initial laboratory assessment 3, 2

LDH is one of five risk factors in the original FLIPI, which stratifies patients into low (0-1 factors), intermediate (2 factors), and high-risk (3-5 factors) groups, as described by the American Society of Hematology (ASH) 1, 4, 5
LDH was replaced by B2M in FLIPI 2, suggesting B2M provides superior prognostic discrimination, according to the ASCO guidelines 1, 3
LDH is still measured routinely at diagnosis per ESMO guidelines, but its primary utility is now for calculating the original FLIPI score rather than the more refined FLIPI 2 or PRIMA-PI 3

For prognostic assessment in follicular lymphoma, measure both B2M and LDH at diagnosis, and calculate FLIPI 2 score (preferred for modern risk stratification) using elevated B2M, largest lymph node diameter >6 cm, bone marrow involvement, hemoglobin <12 g/dL, and age >60 years, as recommended by the NCCN 3, 2, 1
Calculate PRIMA-PI for patients requiring treatment, using B2M elevation as the primary determinant (high risk if elevated, regardless of other factors), according to the ESMO guidelines 1, 3, 2